Cipla USA Inc. recalls Lanreotide injection batches, causing a temporary shortage. The recall follows US FDA’s OAI classification of Pharmathen’s facility in Greece. Production may resume by Q4.
Cipla USA Inc. recalls Lanreotide injection batches, causing a temporary shortage. The recall follows US FDA’s OAI classification of Pharmathen’s facility in Greece. Production may resume by Q4.